In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
出版年份 2019 全文链接
标题
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
作者
关键词
-
出版物
CLINICAL INFECTIOUS DISEASES
Volume 69, Issue Supplement_7, Pages S544-S551
出版商
Oxford University Press (OUP)
发表日期
2019-09-05
DOI
10.1093/cid/ciz827
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
- (2019) George G. Zhanel et al. DRUGS
- A Novel Algorithm to Analyze Epidemiology and Outcomes of Carbapenem Resistance Among Patients With Hospital-Acquired and Ventilator-Associated Pneumonia
- (2019) Marya D. Zilberberg et al. CHEST
- Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
- (2019) Takafumi Sato et al. CLINICAL INFECTIOUS DISEASES
- Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
- (2019) Patrice Nordmann et al. CLINICAL INFECTIOUS DISEASES
- Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
- (2019) Yohei Doi CLINICAL INFECTIOUS DISEASES
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
- (2018) Evelina Tacconelli et al. LANCET INFECTIOUS DISEASES
- Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa
- (2018) Islam M. Ghazi et al. PHARMACOLOGY
- ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
- (2018) Michael R. Jacobs et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
- (2018) James A. Karlowsky et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Stability of cefiderocol against clinically significant broad-spectrum oxacillinases
- (2018) Laurent Poirel et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
- (2018) Krystyna M. Kazmierczak et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
- (2018) Simon Portsmouth et al. LANCET INFECTIOUS DISEASES
- 1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients
- (2018) Kenneth V I Rolston et al. Open Forum Infectious Diseases
- 1349. Global Surveillance of Cefiderocol Against Gram-Negative Clinical Strains Collected in North America: SIDERO-WT-2015
- (2018) Masakatsu Tsuji et al. Open Forum Infectious Diseases
- Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens
- (2017) J. Dobias et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
- (2017) Matthew E. Falagas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates Collected from Urinary Track Source: SIDERO-WT-2014/SIDERO-WT-2015
- (2017) Masakatsu Tsuji et al. Open Forum Infectious Diseases
- In vitro Activity of Cefiderocol against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Track Source: SIDERO-CR-2014/2016
- (2017) Masakatsu Tsuji et al. Open Forum Infectious Diseases
- Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases
- (2016) Tsukasa Ito-Horiyama et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Antibacterial Activity of S-649266 against Gram-negative Clinical Strains Collected in North America and Europe, 2015
- (2016) Meredith Hackel et al. Open Forum Infectious Diseases
- Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
- (2015) Ya-Ting Chang et al. Frontiers in Microbiology
- Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
- (2012) J. S. Brooke CLINICAL MICROBIOLOGY REVIEWS
- Cation Concentration Variability of Four Distinct Mueller-Hinton Agar Brands Influences Polymyxin B Susceptibility Results
- (2012) R. Girardello et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Stenotrophomonas maltophilia: an emerging opportunist human pathogen
- (2009) W John Looney et al. LANCET INFECTIOUS DISEASES
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now